US Stock Market Closed

Dashboard

Regulus Therapeutics, Inc. (RGLS)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

S

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.

CEO

Joseph P. Hagan

Employees

21

Industry

-

Sector

-

Headquarters

San Diego

Exchange

NASDAQ

Summary Stats

Market Cap

24.6M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 3 analysts

High

$1.00

Average

$1.00

Low

$0.00

Ratings calculated by 4 analysts

Buy

1

Hold

3

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by -$0.01

Actual

-$0.50 -2.0%

Consensus

-0.49

Report Date

Year Ago

-0.1

Year Ago Change %

Down 400%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites